Analysts Turn Upbeat on UnitedHealth, Lifting Price Targets for a 2026 Reset
Analysts credit expected margin repair alongside Optum Rx's cost-based contracts for improving recovery prospects.
Overview
- Barclays raised its UnitedHealth price target to $391 on Jan. 5 with an Overweight rating, citing potential margin expansion and a rotation away from AI favorites.
- Bernstein lifted its target to $444 on Jan. 6, and Evercore ISI began coverage at Outperform with a $400 target, describing 2026 as a transition year with stronger improvement projected for 2027–2028.
- RBC reaffirmed a Buy with a $408 target on Dec. 19 after UnitedHealth detailed Optum Rx’s shift to cost-based pharmacy reimbursement across its network.
- UnitedHealth said 100% of community and independent pharmacies in the Optum Rx network have moved to the new model, representing partnerships with more than 17,000 community pharmacies.
- The reassessment follows a difficult 2025 in which the company suspended guidance after its first earnings miss in over a decade and the stock fell about 35%, with investors now eyeing 2026 guidance against a stated 2025 adjusted EPS floor of at least $16.25.